Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Lung Cancer|August 16, 2005
Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancerJenny T Mao, Xiaoyan Cui, Karen Reckamp, et al.
Journal of Translational Medicine|July 23, 2008
Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancerFelicita Baratelli, Hiroko Takedatsu, Saswati Hazra, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 11, 2014
Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancyElvira L Liclican, Tonya C Walser, Saswati Hazra, et al.
American Journal of Translational Research|August 25, 2010
PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancerFelicita Baratelli, Jay M Lee, Saswati Hazra, et al.
Expert Review of Anticancer Therapy|October 20, 2007
Inflammation and lung carcinogenesis: applying findings in prevention and treatmentKatherine A Peebles, Jay M Lee, Jenny T Mao, et al.
British Journal of Cancer|October 8, 2021
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin gradeRobin Kate Kelley, Rebecca Miksad, Irfan Cicin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
Proinflammatory mediators upregulate snail in head and neck squamous cell carcinomaMaie A St John, Mariam Dohadwala, Jie Luo, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
The Lancet. Oncology|July 7, 2022
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialRobin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, et al.
Science Signaling|March 27, 2014
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancerJessica J Tao, Pau Castel, Nina Radosevic-Robin, et al.
Pageof 2